Active immunotherapeutic approaches targeting Aß or tau-related pathologies in transgenic mice have shown promising outcomes in terms of reduction in the extent and progression of AD-like pathologies, reducing inflammation, improving cognitive performance, and reducing memory loss [12-16]. Here, MAPT is linked to Alzheimer disease.